A real-time tracking technology for prostate radiation delivery will be made available to more European patients under a new distribution agreement.
Calypso Medical Technologies has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.
Siemens will retain non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for three years.
Calypso's GPS for the Body tumour localisation system, which has received CE Mark approval, uses miniaturised implanted devices to track the location of tumours for improved accuracy of radiation therapy delivery.
The system enables doctors to localise and track the tumour before and during each radiation treatment. When it moves outside the field of radiation, therapy can be stopped while the patient is repositioned to ensure that the tumour receives the radiation dose.
Unlike other tumour targeting systems, GPS for the Body provides continuous tumour position information without ionising radiation, thereby safeguarding the patient from non-therapeutic radiation.
The Calypso system can be integrated with the Siemens Artiste linear accelerator and other Siemens radiotherapy systems.
"Our distribution agreement with Siemens Healthcare marks an important milestone in our international expansion," said Jed Palmacci, Vice President of Global Sales for Calypso Medical. "This agreement extends the availability of our GPS for the Body technology into geographic areas with significant incidences of prostate cancer. We are pleased that our real-time tracking technology will now serve a new patient base."
"This distribution agreement with Calypso Medical allows us to offer our customers a comprehensive, state-of-the-art cancer treatment solution," said Holger Schmidt, CEO of Oncology Care Systems, Siemens Healthcare. "We are pleased to represent Calypso's technology throughout the European market."